Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 11/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917113 | 0.93 | TYRO3 (0.45) | TYRO3SMN1; SMN2BTKALDH1A1TSHR | |
| SCHEMBL3285506 | 0.86 | PGK1 (0.52) | TYRO3SMN1; SMN2BTKALDH1A1PTK2 | |
| SCHEMBL1917442 | 0.86 | TYRO3 (0.48) | TYRO3SMN1; SMN2BTKALDH1A1TSHR | |
| SCHEMBL1917254 | 0.86 | AXL (0.48) | TYRO3SMN1; SMN2BTKALDH1A1TSHR | |
| SCHEMBL1917416 | 0.85 | AXL (0.43) | TYRO3SMN1; SMN2ALDH1A1IRAK4PGK1 | |
| SCHEMBL3290772 | 0.85 | CHEK1 (0.58) | TYRO3PTK2 | |
| SCHEMBL1917063 | 0.85 | STK17A (0.50) | TYRO3SMN1; SMN2ALDH1A1IRAK4PGK1 | |
| SCHEMBL3291122 | 0.84 | GSK3B (0.58) | TYRO3BTKALDH1A1TSHRPTK2 | |
| SCHEMBL1917661 | 0.80 | SYK (0.45) | TYRO3SMN1; SMN2BTKALDH1A1TSHR | |
| SCHEMBL1917339 | 0.80 | STK17A (0.51) | TYRO3SMN1; SMN2BTKALDH1A1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | TYRO3 2650/4885SMN1; SMN2 1172/4885BTK 1269/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | TYRO3 967/4885SMN1; SMN2 907/4885BTK 442/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | TYRO3 2650/4885SMN1; SMN2 1172/4885BTK 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.